Retromer logo

Our Mission

As world experts in the endolysosomal system, we are pioneering a new class of disease-modifying therapeutics for neurodegenerative diseases.

The chances of developing a neurodegenerative disease increase with age. These diseases affect almost 50 percent of people over age 90. With increases in life expectancy, this problem will eventually have devastating impacts on every family directly. In addition, it will create an enormous, unsustainable financial burden on the healthcare system.

 
 

Leadership

To deliver on the therapeutic potential of our foundational science, we have assembled a team with decades of experience in drug development and neurodegenerative disease. We are open to new partnerships with those interested in joining us in this endeavor.

Leadership

1

Leadership Team

1
2

Scientific Advisory Board

2
3

Collaborators

3

Leadership Team

Joel Klein, J.D. - <p>Chief Executive Officer</p>

Joel Klein, J.D.

Chief Executive Officer

Robert Armstrong, Ph.D. - <p>Chairman, Head of Research &#038; Development</p>

Robert Armstrong, Ph.D.

Chairman, Head of Research & Development

Kalpana Merchant, Ph.D. - <p>Chief Scientific Officer</p>

Kalpana Merchant, Ph.D.

Chief Scientific Officer

Scott Small, M.D. - <p>Scientific Co-founder</p>

Scott Small, M.D.

Scientific Co-founder

Gregory A. Petsko, D.Phil. - <p>Scientific Co-founder</p>

Gregory A. Petsko, D.Phil.

Scientific Co-founder

George Montgomery - <p>Chief Financial Officer</p>

George Montgomery

Chief Financial Officer

vector-line

Our mission is to develop safe and effective therapies for neurodegenerative diseases. Learn more about how we are contributing to research in this area through our science.